Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.

Humans Female Breast Neoplasms / drug therapy Receptor, ErbB-3 / metabolism Receptor, ErbB-2 / metabolism Antibodies, Monoclonal, Humanized / therapeutic use Broadly Neutralizing Antibodies / therapeutic use Middle Aged Antibodies, Monoclonal / therapeutic use Adult Aged Animals Tumor Suppressor Protein p53 / genetics Mutation Mice Antineoplastic Agents / therapeutic use Treatment Outcome Trastuzumab Camptothecin / analogs & derivatives Immunoconjugates

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 Jul 2024
Historique:
received: 18 09 2023
accepted: 26 06 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: epublish

Résumé

Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd's response in women with early-stage hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer. In the SOLTI-1805 TOT-HER3 trial, a single HER3-DXd dose was administered to 98 patients across two parts: 78 patients received 6.4 mg/kg (Part A), and 44 received a lower 5.6 mg/kg dose (Part B). The CelTIL score, measuring tumor cellularity and infiltrating lymphocytes from baseline to day 21, was used to assess drug activity. Part A demonstrated increased CelTIL score after one dose of HER3-DXd. Here we report CelTIL score and safety for Part B. In addition, the exploratory analyses of part A involve a comprehensive study of gene expression, somatic mutations, copy-number segments, and DNA-based subtypes, while Part B focuses on validating gene expression. RNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6). DNA findings indicate that CelTIL response is significantly associated with TP53 mutations, proliferation, non-luminal signatures, and a distinct DNA-based subtype (DNADX cluster-3). Critically, low HER2DX ERBB2 mRNA, correlates with increased HER3-DXd activity, which is validated through in vivo patient-derived xenograft  models. This study proposes chemosensitivity determinants, DNA-based subtype classification, and low ERBB2 expression as potential markers for HER3-DXd activity in HER2-negative breast cancer.

Identifiants

DOI: 10.1038/s41467-024-50056-y PMID: 38992028
pubmed: 38992028
doi: 10.1038/s41467-024-50056-y
pii: 10.1038/s41467-024-50056-y
doi:

Substances chimiques

Receptor, ErbB-3 EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1
ERBB3 protein, human EC 2.7.10.1
Antibodies, Monoclonal, Humanized 0
ERBB2 protein, human EC 2.7.10.1
patritumab 86780VJI1Q
Broadly Neutralizing Antibodies 0
Antibodies, Monoclonal 0
trastuzumab deruxtecan 5384HK7574
Tumor Suppressor Protein p53 0
Antineoplastic Agents 0
TP53 protein, human 0
Trastuzumab P188ANX8CK
Camptothecin XT3Z54Z28A
Immunoconjugates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5826

Subventions

Organisme : Breast Cancer Research Foundation (BCRF)
ID : BCRF-23-198

Informations de copyright

© 2024. The Author(s).

Références

Baselga, J. & Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463–475 (2009).
pubmed: 19536107 doi: 10.1038/nrc2656
Liu, X. et al. Development of effective therapeutics targeting HER3 for cancer treatment. Biol. Proced. Online 21, 1–10 (2019).
doi: 10.1186/s12575-019-0093-1
Mota, J. M. et al. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. Oncotarget 8, 89284–89306 (2017).
pubmed: 29179520 pmcid: 5687690 doi: 10.18632/oncotarget.18467
Hashimoto, Y. et al. A novel HER3-targeting antibody–drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin. Cancer Res. 25, 7151–7161 (2019).
pubmed: 31471314 doi: 10.1158/1078-0432.CCR-19-1745
Jänne, P. A. et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non–small cell lung cancer. Cancer Discov. 12, 74–89 (2022).
pubmed: 34548309 doi: 10.1158/2159-8290.CD-21-0715
Krop, I. E. et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II Trial. J. Clin. Oncol. 41, 5550–5560 (2023).
pubmed: 37801674 pmcid: 10730028 doi: 10.1200/JCO.23.00882
Oliveira, M. et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from Part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Anna. Oncol. 0 (2023).
Oliveira, M. et al. 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial. ESMO Open 8, 101463 (2023).
doi: 10.1016/j.esmoop.2023.101463
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. NEJMoa1914510 https://doi.org/10.1056/NEJMoa1914510 (2019).
Williams, M., Spreafico, A., Vashisht, K. & Hinrichs, M. J. Patient selection strategies to maximize therapeutic index of antibody–drug conjugates: Prior approaches and future directions. Mol. Cancer Ther. 19, 1770–1783 (2020).
pubmed: 32546659 doi: 10.1158/1535-7163.MCT-19-0993
Nuciforo, P. et al. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. Ann. Oncol. 29, 170–177 (2018).
pubmed: 29045543 doi: 10.1093/annonc/mdx647
Chic, N. et al. Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer. J. Natl Cancer Inst. https://doi.org/10.1093/JNCI/DJAB057 (2021).
González-Farré, B. et al. 15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): a SOLTI biomarker analysis. Ann Oncol. 31, S22 (2020).
doi: 10.1016/j.annonc.2020.03.151
Pascual, T. et al. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. npj Breast Cancer 7, 1–11 (2021).
pubmed: 33397968 pmcid: 7782714 doi: 10.1038/s41523-021-00351-4
Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305, 1873–1881 (2011).
pubmed: 21558518 pmcid: 5638042 doi: 10.1001/jama.2011.593
Òdena, A. et al. Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs). Cancer Res. 82, P5-13–14 (2022).
Xia, Y., Fan, C., Hoadley, K. A., Parker, J. S. & Perou, C. M. Genetic determinants of the molecular portraits of epithelial cancers. Nat. Commun. 10, 1–13 (2019).
doi: 10.1038/s41467-019-13588-2
Prat, A. et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat. Commun. 14, 1–16 (2023).
doi: 10.1038/s41467-023-36801-9
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
pubmed: 22522925 pmcid: 3440846 doi: 10.1038/nature10983
Barroso-Sousa, R. & Tolaney, S. M. Clinical development of new antibody–drug conjugates in breast cancer: to infinity and beyond. BioDrugs 35, 159–174 (2021).
pubmed: 33666903 pmcid: 7933915 doi: 10.1007/s40259-021-00472-z
Criscitiello, C., Morganti, S. & Curigliano, G. Antibody–drug conjugates in solid tumors: a look into novel targets. J. Hematol. Oncol.14, 1–18 (2021).
doi: 10.1186/s13045-021-01035-z
Brasó-Maristany, F. et al. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. J. Natl Cancer Inst. https://doi.org/10.1093/JNCI/DJAC227 (2022).
de Haas, S. L. et al. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 25, 2 (2023).
pubmed: 36631725 pmcid: 9832665 doi: 10.1186/s13058-022-01587-z
Bardia, A. et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32, 1148–1156 (2021).
pubmed: 34116144 doi: 10.1016/j.annonc.2021.06.002
Koganemaru, S. et al. U3-1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer. Mol. Cancer Ther. 18, 2043–2050 (2019).
pubmed: 31395690 doi: 10.1158/1535-7163.MCT-19-0452
Haratani, K. et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J. Clin. Invest. 130, 374–388 (2020).
pubmed: 31661465 doi: 10.1172/JCI126598
Pascual, T. et al. SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer. Front. Oncol. 11, 685 (2021).
doi: 10.3389/fonc.2021.638482
Prat, A. et al. Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the Prosigna assay. Clin. Cancer Res. 22, 560–566 (2016).
pubmed: 26152740 doi: 10.1158/1078-0432.CCR-15-0630
Prat, A. et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br. J. Cancer 111, 1532–1541 (2014).
pubmed: 25101563 pmcid: 4200088 doi: 10.1038/bjc.2014.444
Pascual, T. et al. Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy. Clin. Cancer Res. 27, 3116–3125 (2021).
pubmed: 33632929 pmcid: 8172481 doi: 10.1158/1078-0432.CCR-20-4102
Prat, A. et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin. Cancer Res. 23, 3035–3044 (2017).
pubmed: 27903675 doi: 10.1158/1078-0432.CCR-16-2092
Shahbandi, A., Nguyen, H. D. & Jackson, J. G. TP53 mutations and outcomes in breast cancer: reading beyond the headlines. Trends Cancer 6, 98 (2020).
pubmed: 32061310 pmcid: 7931175 doi: 10.1016/j.trecan.2020.01.007
Drago, J. Z., Ferraro, E., Abuhadra, N. & Modi, S. Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev. 109, 102436 (2022).
pubmed: 35870237 pmcid: 10478787 doi: 10.1016/j.ctrv.2022.102436
Diwanji, D. et al. Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface. Nature 600, 339–343 (2021).
pubmed: 34759323 pmcid: 9298180 doi: 10.1038/s41586-021-04084-z
Weitsman, G. et al. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget 7, 51012–51026 (2016).
pubmed: 27618787 pmcid: 5239455 doi: 10.18632/oncotarget.9963
Griguolo, G. et al. ERBB2 mRNA expression and response to ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Cancers (Basel) 12, 1902 (2020).
pubmed: 32674482 doi: 10.3390/cancers12071902
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl.J. Med. 387, 9–20 (2022).
pubmed: 35665782 pmcid: 10561652 doi: 10.1056/NEJMoa2203690
Hurvitz, S. A. et al. TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. J. Clin. Oncol. 39, TPS603–TPS603 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.TPS603
Geyer, C. E. et al. Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05). Cancer Res. 81, OT-03-01 (2021).
Iwata, H. et al. Phase 1/2 Study of HER3-DXd in HER3-expressing metastatic breast cancer: subgroup analysis by HER2 expression. Japan. Soc. Med. Oncol. (2023).
Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110–2120 (2023).
pubmed: 37488289 pmcid: 10427426 doi: 10.1038/s41591-023-02478-2
Diéras, V. et al. Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). Cancer Res. 82, PD8–PD02 (2022).
doi: 10.1158/1538-7445.SABCS21-PD8-02
Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).
pubmed: 25214542 doi: 10.1093/annonc/mdu450
Dieci, M. V. et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin. Cancer Biol. 52, 16–25 (2018).
Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society Of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105–2122 (2018).
pubmed: 29846122 doi: 10.1200/JCO.2018.77.8738
Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317–325 (2008).
pubmed: 18278033 doi: 10.1038/nbt1385
Prat, A. et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine 75, 103801 (2022).
pubmed: 34990895 pmcid: 8741424 doi: 10.1016/j.ebiom.2021.103801
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
pubmed: 19204204 pmcid: 2667820 doi: 10.1200/JCO.2008.18.1370
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401 (2012).
pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095

Auteurs

Fara Brasó-Maristany (F)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Reveal Genomics, Barcelona, Spain.
Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.
ORCID: 0000-0001-5440-9643

Juan Manuel Ferrero-Cafiero (JM)

SOLTI Cancer Research Group, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.
ORCID: 0000-0001-8796-8812

Claudette Falato (C)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.

Olga Martínez-Sáez (O)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.
ORCID: 0000-0001-8686-0236

Juan Miguel Cejalvo (JM)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Breast Cancer Biology Research Group, Biomedical Research Institute INCLIVA, Valencia, Spain.

Mireia Margelí (M)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, Spain.

Pablo Tolosa (P)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.

Francisco Javier Salvador-Bofill (FJ)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.

Josefina Cruz (J)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

Blanca González-Farré (B)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Pathology Department, Hospital Clinic of Barcelona, Barcelona, Spain.

Esther Sanfeliu (E)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Pathology Department, Hospital Clinic of Barcelona, Barcelona, Spain.

Andreu Òdena (A)

University of Barcelona, Barcelona, Spain.
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID: 0000-0003-1529-880X

Violeta Serra (V)

Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID: 0000-0001-6620-1065

Francisco Pardo (F)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Reveal Genomics, Barcelona, Spain.
ORCID: 0000-0002-3067-0166

Ana María Luna Barrera (AM)

Centro Integral Oncológico Clara Campal HM (CIOCC), Madrid, Spain.

Miriam Arumi (M)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Juan Antonio Guerra (JA)

Medical Oncology Department, Hospital de Fuenlabrada, Madrid, Spain.

Guillermo Villacampa (G)

SOLTI Cancer Research Group, Barcelona, Spain.

Rodrigo Sánchez-Bayona (R)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.

Eva Ciruelos (E)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain.

Martín Espinosa-Bravo (M)

SOLTI Cancer Research Group, Barcelona, Spain.
Breast Cancer Surgical Unit, Vall d' Hebron University Hospital, Barcelona, Spain.
ORCID: 0000-0002-4293-3875

Yann Izarzugaza (Y)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Fundación Jimenez Díaz, Madrid, Spain.

Patricia Galván (P)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Reveal Genomics, Barcelona, Spain.

Judith Matito (J)

Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Sonia Pernas (S)

SOLTI Cancer Research Group, Barcelona, Spain.
Bellvitge Biomedical Research Institute IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Medical Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
ORCID: 0000-0002-1485-5080

Maria Vidal (M)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.
ORCID: 0000-0003-1992-5727

Anu Santhanagopal (A)

Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Dalila Sellami (D)

Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Stephen Esker (S)

Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Pang-Dian Fan (PD)

Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Fumitaka Suto (F)

Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.
ORCID: 0009-0009-5649-2650

Ana Vivancos (A)

Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ORCID: 0000-0003-2888-6512

Tomás Pascual (T)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain.
Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona, Barcelona, Spain.
ORCID: 0000-0001-8431-3183

Aleix Prat (A)

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.
SOLTI Cancer Research Group, Barcelona, Spain. alprat@clinic.cat.
Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.
Cancer Institute and Blood Diseases, Hospital Clinic de Barcelona, Barcelona, Spain. alprat@clinic.cat.
Department of Medicine, University of Barcelona, Barcelona, Spain. alprat@clinic.cat.
Institute of Oncology (IOB)-Hospital Quirónsalud, Barcelona, Spain. alprat@clinic.cat.
ORCID: 0000-0003-2377-540X

Mafalda Oliveira (M)

SOLTI Cancer Research Group, Barcelona, Spain.
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-3 › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Anticorps neutralisants à large spectre › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Eucaryotes › Animaux › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Phénomènes génétiques › Variation génétique › Mutation › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Trastuzumab › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Composés hétérocycliques › Alcaloïdes › Camptothécine › Patritumab deruxtecan in HER2-negative breast...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Patritumab deruxtecan in HER2-negative breast...